nach oben

Drug Safety

Erschienen in:

01.05.2000 | Review Article

Benefits and Risks of Minocycline in Rheumatoid Arthritis

verfasst von: Dr Pnina Langevitz, Avi Livneh, Ilan Bank, Mordechai Pras

Erschienen in: Drug Safety | Ausgabe 5/2000

Einloggen, um Zugang zu erhalten

Abstract

Rheumatoid arthritis is a chronic inflammatory disease affecting about 1% of the adult population. The pathophysiology of rheumatoid arthritis remains incompletely understood. An infectious aetiology of the disease has long been postulated, but not proved. Despite insufficient evidence for the infectious nature of this disorder, several antibacterials, such as sulfa compounds, tetracyclines and rifampicin, have been investigated in the treatment of rheumatoid arthritis.

In the last few years, minocycline, a semi-synthetic derivative of tetracycline, has been extensively studied as a therapeutic agent for rheumatoid arthritis. The antirheumatic effect of minocycline can be related to its immunomodulatory and anti-inflammatory, rather than to its antibacterial properties. Its efficacy in rheumatoid arthritis has been reported in 2 open trials and in 3 double-blind controlled studies. The first 2 double-blind studies, 1 in The Netherlands and 1 in the US, were performed in patients with advanced disease. Both studies showed a modest, but statistically significant improvement in the clinical parameters of disease activity and in the erythrocyte sedimentation rate in the minocycline-treated patients. The US study also reported that patients in the minocycline group developed fewer erosions than those in the placebo group. This finding supports the role of minocycline as a disease modifying agent. The common adverse effects of minocycline reported in these 2 studies included gastrointestinal adverse effects, dizziness, rash and headaches. Less common adverse effects were intracranial hypertension, pneumonitis, persistent skin and mucosal hyperpigmentation, lupus-like syndrome and acute hepatic injury.

The third double-blind study enrolled only seropositive rheumatoid arthritis patients with early disease (less than 1 year duration), and showed very encouraging results of significant improvement in the disease activity parameters in the minocycline treated group of patients. The same authors later reported that about half of these patients were in or near remission after 3 years of follow up. No adverse effects were reported in this study.

Summarising the data of these 3 double-blind studies, we may conclude that minocycline may be beneficial in patients with rheumatoid arthritis, especially when given early in the disease course or in patients with a mild disease.

Wollheim FA. Rheumatoid arthritis. In: Maddison PJ, Isenberg DA, Woo P, et al., editors. Oxford textbook of rheumatology. 2nd ed. Oxford; Oxford Medical Publications, 1998: 1018–31

Felson DT, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis: results of two metaanalyses. Arthritis Rheum 1990; 33: 1449–61PubMed

Felson DT, Anderson JJ, Meeman RF. Use of short-term efficacy-toxicity trade-offs to select second-line drugs in rheumatoid arthritis: a metaanalysis of published clinical trials. Arthritis Rheum 1992; 35: 1117–25PubMed

Morand EF, McCloud PI, Littlejohn GO. Life table analysis of 879 treatment episodes with slow acting antirheumatic drugs in community rheumatology practice. J Rheumatol 1992; 19: 704–8PubMed

Wolfe F, Hawley DJ, Cathey MA. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol 1990; 17: 994–1002PubMed

Bartolomew IE. Isolation and characterization of mycoplasma (PPLO) in patients with rheumatoid arthritis, systemic lupus erythematosus and Reiter’s syndrome. Arthritis Rheum 1965; 8: 376–88

Brown T, Bush SW, Felts WR. In: Wohl MG, editor. Long-term illness: management of the chronically ill patient. Philadelphia: WB Saunders, 1959: 93–125

Sanchez I. Tetracyclines treatment in rheumatoid arthritis and other rheumatic diseases. Brazil Med 1968; 82: 22–31

Sande MA, Mandell GL. Antimicrobial agents. Tetracyclines. In: Gilman A, Goodman LS, Rall TW, editors. Goodman and Gilman’s the pharmacological basis of therapeutics. 7th ed. New York (NY): Macmillan Publishing Co, 1980: 1170–9

10.

Golub LM, McNamara TF, D’Angelo G, et al. A non-antibacterial, chemically-modified tetracycline inhibits mammalian collagenase activity. J Dent Res 1987; 66: 1310–4PubMed

11.

Golub LM, Ramamurthy NS, McNamara TF, et.al. Tetracyclines inhibit tissue collagenase activity: a new mechanism in the treatment of periodontal disease. Periodontal Res 1984; 19: 651–5

12.

Golub LM, Suomalainen K, Sorsa T, et al. Host modulation with tetracyclines and their chemically modified analogues. Curr Opin Dent 1992; 2: 80–90PubMed

13.

Greenwald RA, Golub LM, Lavietes B, et al. Tetracyclines inhibit human synovial collagenese in vivo and in vitro. J Rheumatol 1987; 14: 28–32PubMed

14.

Golub LM, Lee HM, Lehrer G, et al. Minocycline reduces gingival collagenonic activity during diabetes: preliminary observations and a proposed new mechanism of action. J Periodontal 1983; 18: 516–24

15.

Golub LM, Wolf M, Lee HM, et al. Further evidence that tetracyclines inhibit collagenase activity in human crevicular fluid and from other mammalian sources. J Periodontal Res 1985; 20: 12–23PubMed

16.

Rifkin RB, Colub LM, Sanavi R, et al. Effects of tetracyclines on rat osteoblast collagenase activity and bone resorption in vitro. In: Davidovich Z, editor. The biological mechanisms of tooth movement and craniofacial adaptation. Birmingham: EBSCO, 1992: 85–90

17.

Yu LPJ, Smith GNJ, Hasty KA, et al. Doxycycline inhibits type XI collagenolytic activity of extracts from human osteoarthritic cartilage and of gelatinase. J Rheumatol 1991; 18: 1450–2PubMed

18.

Pruzanski W, Greenwald RA, Street IP, et al. Inhibition of enzymatic activity of phospholipases A2 by minocycline and doxycycline. Biochem Pharmacol 1992; 44: 1165–70PubMed

19.

Vadas P, Pruzanski W, Kim J, et al. The proinflammatory effect of the intraarticular injection of soluble venom and human phospholipase A2. Am J Pathol 1988; 134: 807–11

20.

Bomalski JS, Lawton P, Browning JL. Human extracellular recombinant phospholipase A2 induces an inflammatory response in rabbit joints. J Rheumatol 1991; 146: 3904–10

21.

Breedveld FC, O’Brien JM, Brinckerhoff CE, et al. Suppression of collagen and adjuvant arthritis by a tetracycline [abstract]. Arthritis Rheum 1988; Suppl. 31: 588

22.

Sewell KI, Furrie E, Trentham DE. The therapeutic effect of minocycline in experimental arthritis: mechanism of action [abstract]. Arthritis Rheum 1991; Suppl. 33: S106

23.

Sewell KL, Fury E, Dynesius-Trentham R, et al. Evidence that minocycline suppress collagen and adjuvant arthritis by altering the expression of T cell derived, collagen-binding proteins [abstract]. Arthritis Rheum 1989; Suppl 32: S134

24.

Greenwald RA, Moak SA, Ramamurthy NSD, et al. Tetracyclines suppress metalloproteinase activity in adjuvant arthritis and, in combination flurbiprofen, ameliorate bone damage. J Rheumatol 1992; 19: 927–38PubMed

25.

El Attar TMA, Lin HS, Schulz R. Effect of minocycline on prostaglandin formation in gingival fibroblasts. J Periodontal Res 1988; 23: 285–6

26.

Martin RR, Warr GA, Couch RB, et al. Effects of tetracyclines on leukotaxis. J Infect Dis 1974; 129: 110–6PubMed

27.

Thong YH, Ferrante A. Effect of tetracycline treatment on immunological responses in mice. Clin Exp Immunol 1980; 39: 728–32PubMed

28.

Kloppenburg M, Miltenburg AMM, Vendonk MYA, et al. Minocycline inhibits T-cell proliferation and interferon gamma (IFN-gamma) production after stimulation with anti CD3 monoclonal antibodies [abstract]. Br J Rheumatol 1992; 31Suppl.: 41

29.

Langevitz P, Bank I, Zemer D, et al. Treatment of resistant rheumatoid arthritis with minocycline: an open study. J Rheumatol 1992; 19: 1502–4PubMed

30.

Wasil M, Halliwell B, Moorhouse CP. Scavenging of hypochlorous acid by tetracycline, rifampicin and some other antibiotics: a possible antioxidant action of rifampicin and tetracycline. Biochem Pharmacol 1988; 37: 775–8PubMed

31.

Van Barr HM, van de Kerkhop PC, Mier PD, et al. Tetracyclines are potent scavengers of the superoxide radical. Br J Dermatol 1987; 117: 131–2PubMed

32.

Brown TMcP, Bush SW, Felts WR. In: Wohl MG, editor. Longterm illness: management of the chronically ill patient. Philadelphia: WB Saunders, 1959: 93–125

33.

Sanchez I. Tetracycline treatment in rheumatoid arthritis and other rheumatic diseases [in Portuguese]. Brasil Med 1968; 82: 22–31

34.

Skimer M, Cathcart ES, Mills YA, et al. Tetracycline in the treatment of rheumatoid arthritis. Arthritis Rheum 1971; 14: 727–32

35.

Wright AL, Colver GB. Tetracyclines: how safe are they? Clin Exp Dermatol 1988; 13: 57–61PubMed

36.

Bardin T, Erel C, Cornelis F, et al. Antibiotic treatment of venereal disease and Reiter’s syndrome in Greenland population. Arthritis Rheum 1992; 35: 190–4PubMed

37.

Bardin T, Schumacher HR. Should we treat postvenereal Reiter’s syndrome by antibiotics? J Rheumatol 1991; 18: 1780–2PubMed

38.

Lauhio A, Leirisalo-Repo M, Lahdevirta J, et al. Double-blinded, placebo-controlled study of three-month treatment with lymecycline in reactive arthritis with special reference to chlamidia arthritis. Arthritis Rheum 1991; 34: 6–14PubMed

39.

Breedveld FC, Dijkmans BAC, Mattie H. Minocycline treatment for rheumatoid arthritis: an open dose finding study. J Rheumatol 1990; 17: 43–6PubMed

40.

Kloppenburg M, Breedveld FC, Terwiel JPH, et al. Minocycline in active rheumatoid arthritis: a double-blind, placebo-controlled trial. Arthritis Rheum 1994; 37: 629–36PubMed

41.

Tilley BC, Alarcon GS, Heyse SP, et al., for the MIRA trial group. Minocycline in rheumatoid arthritis: a 48-week, double-blind, placebo-controlled trial. Ann Int Med 1995; 122: 81–9PubMed

42.

O’Dell JR, Haire CE, Palmer W, et al. Treatment of early rheumatoid arthritis with minocycline or placebo. Arthritis Rheum 1997; 40: 842–8PubMed

43.

Bluhm GB, Sharp JT, Tilley B, et al. Radiographic results from the minocycline in rheumatoid arthritis trial (MIRA). J Rheumatol 1997; 24: 1295–302PubMed

44.

O’Dell JR, Paulsen G, Haire LE, et al. Treatment of early seropositive rheumatoid arthritis with minocycline. Four year follow up of a double-blind, placebo controlled study. Arthritis Rheum 1999; 42: 1691–5PubMed

45.

Langevitz P, Bank I, Livneh A, et al. Long-term experience with minocycline in patients with resistant rheumatoid arthritis (RA) [abstract]. Rheumatol Eur 1995; 24 Suppl.: D100

46.

Pruznaski W, Vadas P. Should tetracyclines be used in arthritis? J Rheumatol 1992; 19: 1495–6

47.

Trentham DE, Disenius-Trentham RA. Antibiotic therapy for rheumtoid arthritis: scientific and anecdotal appraisals. Rheum Dis Clin North America 1995; 21: 817–34

48.

Langevitz P, Livneh A, Bank I, et al. Minocycline in rheumatoid arthritis. Isr J Med Sci 1996; 32–4

49.

Alarcon GS. Minocycline for the treatment of rheumatoid arthritis. Rheum Dis Clin North Am 1998; 24: 489–99PubMed

50.

Paulus EH. Minocycline treatment of rheumatoid arthritis. Ann Int Med 1995; 122: 147–8PubMed

51.

Breedveld FC. Minocycline in rheumatoid arthritis. Arthritis Rheum 1997; 40: 794–6PubMed

52.

Kloppenburg M, Mattie H, Dauwes N, et al. Minocycline in the treatment of rheumatoid arthritis: the relationship of serum concentrations to efficacy. J Rheumatol 1995; 22: 611–6PubMed

53.

Malcolm A, Heap TR, Eckstein RP, et al. Minocycline induced liver injury. Am J Gastroenterol 1996; 91: 1641–3PubMed

54.

Golstein PE, Deviere J, Gremer M. Acute hepatitis and drug-related lupus induced by minocycline treatment. Am J Gastroenterol 1997; 92: 143–6PubMed

55.

Beudreaux JP, Hayes DK, Mizrahi S, et al. Fulminant hepatic failure, hepatorenal syndrome and necrotizing pancreatitis after minocycline hepatotoxicity. Transplant Proceed 1993; 25: 1873

56.

Sorbi D, Thistle JR. Minocycline, an unusual cause of drug-induced lupus and autoimmune hepatitis. Am J Gastroenterol 1997; 92: 1732

57.

Hewak J, Teuyses G, Hunt RH. Minocycline induced hepatotoxicity presenting as autoimmune hepatitis: report of three cases [abstract]. Canadian J Gastroenterol 1996; 10 Suppl.: 57

58.

Min DY, Burke PA, Lewis D. Acute hepatic failure associated with oral minocycline: a case report. Pharmacother 1992; 12: 68–71

59.

Ovartlarnporn B, Kuluichit, Hiranniramal S. Medication induced esophageal injury: report of 17 cases with endoscopic determination. Ann J Gastroenterol 1991; 86: 748–50

60.

Puyana J, Urena V, Quirce S, et al. Serum sickness-like syndrome associated with minocycline therapy. Allergy 1990 45: 313–5PubMed

61.

Levenson T, Masood D, Patterson R. Minocycline-induced serum sickness. Allergy Asthma Proceed 1996; 17: 79–81

62.

Harel L, Amir J, Livni E. Serum sickness-like reaction associated with minocycline therapy in adolescents. Ann Pharmacother 1996; 30: 481–3PubMed

63.

Guillon JM, Joly P, Autran B, et al. Minocycline-induced cell-mediated hypersensitivity pneumonitis. Ann Int Med 1992; 117: 476–81PubMed

64.

Dupont C, Rouveix E, Chinet T, et al. Loffler’s syndrome in a minocycline-treated woman. Ann Med Intern 1993; 14: 76

65.

Bentur L, Bar Kana Y, Livni E, et al. Severe minocycline-induced-eosinophilic pneumonia: extrapulmonary manifestations and the use of in vitro immunoassays. Ann Pharmacother 1994; 31: 733–5

66.

Sitbon O, Bidel N, Dussport C, et al. Minocycline pneumonitis and eosinophilia: report on eight patients. Arch Int Med 154: 1633–40

67.

Dykhuizen RS, Zaidi AM, Golden DJ, et al. Minocycline and pulmonary eosinophilia. BMJ 1995; 310: 1520–1PubMed

68.

Toyoshima M, Sato A, Hoyakawa H. A clinical study of minocycline-induced pneumonitis. Int Med 1996; 35: 176–9

69.

Bando T, Fujimura M, Noda Y, et al. Minocycline-induced pneumonitis with bilateral hilar lymphadenopathy and pleural effusion. Int Med 1994; 33: 177–9

70.

Dykhuizen RS, Legge JS. Minocycline induced pulmonary eosinophilia. Resp Med 1995; 89: 61–2

71.

Eisen D, Hakim MD. Minocycline-induced pigmentation: incidence, prevention and management. Drug Saf 1998; 18: 431–40PubMed

72.

Basler RSW. Minocycline-related hyperpigmentation. Arch Dermatol 1985; 121: 606–8PubMed

73.

Dwyer CM, Guddihy AM, Keer REI. Skin pigmentation due to minocycline treatment of facial dermatoses. Br J Dermatol 1993; 129: 158–62PubMed

74.

Okada N, Sato S, Sasou T, et al. Characterization of pigmented granules in minocycline-induced cutaneous pigmentation: observations using fluorescence microscopy and high performance liquid chromatography. Br J Dermatol 1993; 129: 403–7PubMed

75.

Schofield JK, Tatnall FM. Minocycline induced skin pigmentation. Br J Gen Pract 1993; 43: 173–4PubMed

76.

Katz J, Barak S, Shemer J, et al. Black tongue associated with minocycline therapy [letter]. Arch Dermatol 1995; 131: 620PubMed

77.

Hunt MJ, Salisbury ELC, Grace J, et al. Black breast milk due to minocycline therapy. Br J Dermatol 1996; 134: 943–4PubMed

78.

Sabrae RA, Archer CB, Harlow D, et al. Minocycline-induced discoloration of the sclerae. Br J Dermatol 1996; 135: 314–6

79.

Eedy DJ, Burrows D. Minocycline-induced pigmentation occurring in two sisters. Clin Exp Dermatol 1991; 16: 55–7PubMed

80.

Pepine M, Flowers FP, Ramas-Caro FA. Extensive cutaneous hyperpigmentation caused by minocycline. J Am Acad Dermatol 1993; 28: 292–5PubMed

81.

Hung PK, Caldwell JB, James WD. Minocycline-induced hyperpigmentation. J Fam Pract 1995; 41: 183–5PubMed

82.

Fraunfelder FT, Randall JA. Minocycline induced scleral pigmentation. Ophthalmol 1997; 104: 936–8

83.

Purdue B. An incidental autopsy finding of black thyroid associated with minocycline therapy. Med Sci Law 1992; 32: 148–50PubMed

84.

Meyerson MA, Cohen PR, Hymes JR. Lingual hyperpigmentation associated with minocycline therapy. Oral Surg Oral Med Oral Phathol Oral Radiol Endodontics 1995; 79: 180–4

85.

Parkins FM, Furnish G, Bernstein M. Minocycline use discolors teeth. J Am Dent Assoc 1992; 123: 87–9PubMed

86.

Eisen D. Minocycline-induced oral hyperpigmentation [letter]. Lancet 1997; 349: 400PubMed

87.

Rumback MJ, Pitcock JA, Palmieri GMA. Black bones following long-term minocycline treatment. Arch Pathol Lab Med 1991; 115: 939–41

88.

Moritz DL, Elewski B. Pigmented postacne osteomacutis in a patient treated with minocycline: a report and review of the literature. J Am Acad Dermatol 1991; 24: 851–3PubMed

89.

Leffell DJ. Minocycline hydrochoride hyperpigmentation complicating treatment of venous ectasia of the extremities. J Am Acad Dermatol 1991; 24: 501–2PubMed

90.

Butt A, Statham BN. Minocycline-induced hyperpigmentation of basal cell carcinomas. J Dermatol Treat 1998; 9: 39–42

91.

Wilde LJ, English III JC, Finley EM. Minocycline-induced hyperpigmentation: treatment with neodymium: YAG laser. Arch Dermatol 1997; 133: 1344–6PubMed

92.

Matsumura T, Shimizu Y, Fujimoto H, et al. Minocycline induced lupus [letter]. Lancet 1992; 340: 1553

93.

Farver DK. Minocycline-induced lupus. Ann Pharmacother 1997; 31: 1160–3PubMed

94.

Masson C, Pascaretti C, Capon F, et al. Minocyline-related lupus: a review of 23 definite cases [abstract]. Arthritis Rheum 1996; 39 Suppl.: 60

95.

Breedveld FC. Minocycline induced autoimmune disease: reply. Arthritis Rheum 1998; 41: 563–4

96.

Gordon PM, White MI, Herriot R. Minocycline-associated lupus erythematosus. Br J Dermatol 1995; 132: 120–1PubMed

97.

Gendi NST, Bawman SJ, Mowat AG. Lupus-like syndrome in patients treated for acne. Br J Rheumatol 1995; 34: 584–5PubMed

98.

Quilty B, McHugh N. Lupus-like syndrome associated with the use of minocycline. Br J Rheumatol 1994; 33: 1197–8PubMed

99.

Byrne PAC, Williams BD, Pritchard MH. Minocycline-related lupus. Br J Rheumatol 1994; 33: 674–6PubMed

100.

Lauwerys B, Martin F, Mahri A, et al. Minocycline: a common cause of drug-induced lupus. Clin Rheumatol 1997; 16: 520

101.

Gresson J, Stillman MT. Minocycline-related lupus erythematasus with associated liver disease. J Am Acad Dermatol 1997; 36: 867–8

102.

Masson C, Chevailler A, Pascoretti C. Minocycline related lupus. J Rheumatol 1996; 23: 2160–1PubMed

103.

Alain E, Miller LC, Tucker LB. Minocycline-induced lupus in adolescents. Pediatrics 1998; 101: 926–8

104.

Elkayam O, Yaron M, Caspi D. Minocycline induced arthritis associated with fever, livedo reticularis and P-ANCA. Ann Rheum Dis 1996; 55: 769–71PubMed

105.

Alain E, Miller LC, Tucker CB, et al. Minocycline related lupus-like syndrome: possible association with antineutrophil cytoplasmic antibodies. Arthritis Rheum 1997; 40 Suppl.: 191

106.

Elkayam O, Levartovsky D, Brautbar Ch, et al. Clinical and immunological study of 7 patients with minocycline- induced autoimmune phenomena. Am J Med 1998; 105: 484–7PubMed

107.

Boyd I. Benign intracranial hypertension induce by minocycline. Curr Ther 1995; 36: 70–1

108.

Weller M, Klockgether T. Minocycline-induced benign intracranial hypertension [letter]. J Neurol 1988; 245: 55

Titel: Benefits and Risks of Minocycline in Rheumatoid Arthritis
verfasst von: Dr Pnina Langevitz
Avi Livneh
Ilan Bank
Mordechai Pras
Publikationsdatum: 01.05.2000
Verlag: Springer International Publishing
Erschienen in: Drug Safety / Ausgabe 5/2000
Print ISSN: 0114-5916
Elektronische ISSN: 1179-1942
DOI: https://doi.org/10.2165/00002018-200022050-00007

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Benefits and Risks of Minocycline in Rheumatoid Arthritis

Abstract

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2000

Risk-Benefit Ratio of Angiotensin Antagonists versus ACE Inhibitors in End-Stage Renal Disease

Antibacterial Use in Pregnancy

Cardiovascular Events Associated With Different Combined Oral Contraceptives

Comparative Tolerability of Chemotherapy Regimens for Germ Cell Cancer

A Risk-Benefit Assessment of Drugs Used for Neonatal Chronic Lung Disease

Photosensitivity to Ketoprofen